Novel strategies and future landmarks in the treatment of irritable bowel syndrome

R. Róka, Krisztina Gecse, T. Wittmann

Research output: Contribution to journalArticle

Abstract

Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by continuous or remittent abdominal pain, bloating and altered defecation. The population-based prevalence of IBS has been reported to be approximately 3-20%, depending on the diagnostic criteria. Despite intense research in recent decades, the pathogenesis of IBS remains only partially understood, and thus no specific and universally effective patient management has been developed so far. Current therapy for IBS focuses on the major symptoms, while a novel approach in the treatment is based on targeting specific receptors in the gastrointestinal tract that are known to be involved in the pathogenesis of the disease. In view of the severe side effects of early serotonin receptor modulators, a good safety profile is of primary importance in the treatment of functional gastrointestinal disorders. This article provides a pathogenesis-based overview of recently developed pharmaceutics and future perspectives on the therapy of IBS.

Original languageEnglish
Pages (from-to)603-613
Number of pages11
JournalTherapy
Volume6
Issue number4
DOIs
Publication statusPublished - Jul 2009

Fingerprint

Irritable Bowel Syndrome
Gastrointestinal Diseases
Therapeutics
Defecation
Serotonin Receptors
Abdominal Pain
Gastrointestinal Tract
Safety
Research
Pharmaceutical Preparations
Population

Keywords

  • Chloride channel
  • Guanilate cyclase-C
  • Irritable bowel syndrome
  • Neuropeptide
  • Opioid
  • Probiotics
  • Serotonin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Novel strategies and future landmarks in the treatment of irritable bowel syndrome. / Róka, R.; Gecse, Krisztina; Wittmann, T.

In: Therapy, Vol. 6, No. 4, 07.2009, p. 603-613.

Research output: Contribution to journalArticle

@article{4168bbf61cf74d308f3db3eccfc02bda,
title = "Novel strategies and future landmarks in the treatment of irritable bowel syndrome",
abstract = "Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by continuous or remittent abdominal pain, bloating and altered defecation. The population-based prevalence of IBS has been reported to be approximately 3-20{\%}, depending on the diagnostic criteria. Despite intense research in recent decades, the pathogenesis of IBS remains only partially understood, and thus no specific and universally effective patient management has been developed so far. Current therapy for IBS focuses on the major symptoms, while a novel approach in the treatment is based on targeting specific receptors in the gastrointestinal tract that are known to be involved in the pathogenesis of the disease. In view of the severe side effects of early serotonin receptor modulators, a good safety profile is of primary importance in the treatment of functional gastrointestinal disorders. This article provides a pathogenesis-based overview of recently developed pharmaceutics and future perspectives on the therapy of IBS.",
keywords = "Chloride channel, Guanilate cyclase-C, Irritable bowel syndrome, Neuropeptide, Opioid, Probiotics, Serotonin",
author = "R. R{\'o}ka and Krisztina Gecse and T. Wittmann",
year = "2009",
month = "7",
doi = "10.2217/thy.09.22",
language = "English",
volume = "6",
pages = "603--613",
journal = "Therapy",
issn = "2044-9038",
publisher = "Future Medicine Ltd.",
number = "4",

}

TY - JOUR

T1 - Novel strategies and future landmarks in the treatment of irritable bowel syndrome

AU - Róka, R.

AU - Gecse, Krisztina

AU - Wittmann, T.

PY - 2009/7

Y1 - 2009/7

N2 - Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by continuous or remittent abdominal pain, bloating and altered defecation. The population-based prevalence of IBS has been reported to be approximately 3-20%, depending on the diagnostic criteria. Despite intense research in recent decades, the pathogenesis of IBS remains only partially understood, and thus no specific and universally effective patient management has been developed so far. Current therapy for IBS focuses on the major symptoms, while a novel approach in the treatment is based on targeting specific receptors in the gastrointestinal tract that are known to be involved in the pathogenesis of the disease. In view of the severe side effects of early serotonin receptor modulators, a good safety profile is of primary importance in the treatment of functional gastrointestinal disorders. This article provides a pathogenesis-based overview of recently developed pharmaceutics and future perspectives on the therapy of IBS.

AB - Irritable bowel syndrome (IBS) is a chronic functional gastrointestinal disorder characterized by continuous or remittent abdominal pain, bloating and altered defecation. The population-based prevalence of IBS has been reported to be approximately 3-20%, depending on the diagnostic criteria. Despite intense research in recent decades, the pathogenesis of IBS remains only partially understood, and thus no specific and universally effective patient management has been developed so far. Current therapy for IBS focuses on the major symptoms, while a novel approach in the treatment is based on targeting specific receptors in the gastrointestinal tract that are known to be involved in the pathogenesis of the disease. In view of the severe side effects of early serotonin receptor modulators, a good safety profile is of primary importance in the treatment of functional gastrointestinal disorders. This article provides a pathogenesis-based overview of recently developed pharmaceutics and future perspectives on the therapy of IBS.

KW - Chloride channel

KW - Guanilate cyclase-C

KW - Irritable bowel syndrome

KW - Neuropeptide

KW - Opioid

KW - Probiotics

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=70449558145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70449558145&partnerID=8YFLogxK

U2 - 10.2217/thy.09.22

DO - 10.2217/thy.09.22

M3 - Article

VL - 6

SP - 603

EP - 613

JO - Therapy

JF - Therapy

SN - 2044-9038

IS - 4

ER -